ArticleMaterials today. Bio2025
Injectable hyaluronic acid-based hydrogel niches to create localized and time-controlled therapy delivery.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Biomaterial-based extracellular vesicle delivery systems for wound healing: From fabrication to applications.Bioactive materials · 2026Review
- Biomedical Hydrogels Based on Natural Polysaccharides: Structural Design.Gels (Basel, Switzerland) · 2026Review
- Hydrogel-Based Therapeutic Strategies for Post-Cholecystectomy NAFLD: Targeting Bile Acid Signaling, Gut Microbiota, Inflammation, and Hepatic Fibrosis.Gels (Basel, Switzerland) · 2026Review
- Recent advances in polymer-based drug delivery systems for atopic dermatitis: enhancing therapeutic efficacy and outcomes.Materials today. Bio · 2025Review
- Heparin-Based Growth Factor Delivery Platforms: A Review.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of hydrogel-based niches for therapy delivery enables the concentration of active components and cells in a targeted area. This approach enhances efficacy while minimizing systemic side effects by spatially controlling the release of the therapy. Precise tuning of the matrix's chemical properties and control of both material degradation and release profile of biologically active components are required to reduce the optimal dose and extend its therapeutic effect. Here we aimed to develop an injectable hydrogel that can fulfill all these requirements. We designed a system based on hyaluronic acid, crosslinked via click-reaction with multi-arm polyethyleneglycol and functionalized with RGD peptides. Additionally, we incorporated thiol-modified heparin into the formulation, which provides specific binding sites for cytokines. Our results indicate that heparin incorporation can delay cytokine release, while the release of nanocarriers can be regulated by adjusting the crosslinking degree. This design modulates pore size and degradation time, while preserving the injectability of the niche. In conclusion, this system offers a versatile and efficient delivery platform suitable for therapeutic applications in a wide range of diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.